Podcasts about thermo fisher

Sustainability in the lab isn't just a trend—it's a responsibility. In this quick but powerful Mol Bio Minutes episode, sustainability expert Sune Lund Sporring shares actionable tips to reduce energy use, manage lab waste, and transition to greener materials like Thermo Fisher's Sustain Series bio-based plastics.Discover the difference between bio-based and biodegradable, why second-generation feedstocks are a game-changer, and how to make low-impact changes without compromising performance. Learn how small shifts—like using aluminum beads instead of water in a bath or switching to carbon-reduced plastics—can significantly cut your lab's carbon footprint. And remember: if greener options aren't available, your demand can help shape the market.Helpful resource links mentioned in this episode:My Green Lab – Facts and resources about lab sustainabilityEnergy use of fume hoods – Energy use and savings ideas for fume hoodsGreener by Design – Thermo Fisher's approach to green solutionsLab Armor™ Beads – A sustainable option to replace water in water bathsInstrument trade up program – trade in your equipment to be green and give it a second lifeLab plastic waste – Stats about plastic waste in labsDoing something about it – Thermo Fisher's lower carbon plastics solutionSustain Series PCR plastics – Lower carbon footprint, without workflow interruptionReasons to believe – Fact sheet about Sustain Series PCR plastics Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

The good — Thermo Fisher opens center to boost cell therapy development The bad — FDA cites Aurobindo plant after Raleigh inspection The ugly — Trump probes pharma imports as tariff threat looms

Danaher steht nach der Abspaltung von Veralto und mehreren Zukäufen im Biotechnologie-Segment vor einer Phase strategischer Neupositionierung. Unter der Leitung von CEO Rainer M. Blair verfolgt das Unternehmen das Ziel, durch den Fokus auf Biotech und Diagnostik neue Wachstumsimpulse zu setzen. Gleichzeitig belasten ein schwächerer Ausblick und enttäuschende Quartalszahlen die Kursentwicklung. Seit der Corona-Pandemie verzeichnete Danaher zunächst außergewöhnliche Umsatz- und Ergebniszuwächse, die maßgeblich vom temporären COVID-19-Geschäft profitierten. Mit dem Wegfall dieses Sondereffekts normalisieren sich die Kennzahlen, während Investoren den Erfolg der Neuausrichtung kritisch bewerten. Die Analyse beleuchtet die operative Entwicklung der vergangenen Jahre, die strategische Positionierung im Markt, die Rolle des Managements sowie die finanzielle Situation des Konzerns. Im Fokus stehen zudem die Entwicklung der Margen, der Cashflows und der Bewertung im historischen und sektoralen Vergleich. Ergänzend erfolgt eine technische Analyse, die die aktuelle charttechnische Ausgangslage einordnet. Danaher steht damit an einem Wendepunkt: Die Frage, ob der Wandel hin zu einem fokussierten Biotech- und Diagnostikkonzern gelingen kann, bleibt offen. Inhaltsverzeichnis00:00 Intro00:53 Langfristiger Chart: Danaher vs. vergangene Videos02:43 Danaher vs. S&P 500 vs. Gesundheits-ETF (XLV) vs. Sartorius vs. Thermo Fisher vs. Agilent vs. Abbott vs. Illumina03:22 Danaher: Geschäftsmodell05:04 Letze Quartalszahlen06:45 Übernahmen & Zukäufe09:04 Anteil an wiederkehrenden Einnahmen11:16 Burggraben: Danaher12:11 Inhaberschaft & CEO13:47 Umsatz- & Margen-Entwicklung vs. Video aus 202314:22 Umsatz nach Segment & Region16:27 Gewinn, Cashflow & Dividenden-Entwicklung vs. Video aus 202318:53 Bilanz-Überblick & Aktienrückkäufe20:53 Kennzahlen-Überblick (KGV)21:40 Dividenden-Rendite & -Entwicklung22:11 Unternehmensbewertung: Allianz vs. Video aus 202323:14 Chartanalyse: Danaher vs. Video aus 202324:27 Ist die Danaher Aktie ein Kauf?26:55 Disclaimer28:38 Danke fürs Einschalten! Zusammenarbeit anfragenhttps://www.maximilian-gamperling.de/termin/ Social Media- Instagram: https://www.instagram.com/maximilian_gamperling/- LinkedIn: https://www.linkedin.com/in/gamperling/- Newsletter: https://www.maximilian-gamperling.de/newsletter- Podcast: https://akademie.maximilian-gamperling.de/podcasts/anker-aktien-podcast Meine Tools- Charts*: https://de.tradingview.com/?aff_id=117182- Aktienfinder: https://aktienfinder.net- Finchat.io*: https://finchat.io/?via=maximilian- TransparentShare: https://bit.ly/3laA6tK- SeekingAlpha*: https://www.sahg6dtr.com/QHJ7RM/R74QP/- Captrader*: https://www.financeads.net/tc.php?t=41972C46922130T DisclaimerAlle Informationen beruhen auf Quellen, die wir für glaubwürdig halten. Trotz sorgfältiger Bearbeitung können wir für die Richtigkeit der Angaben und Kurse keine Gewähr übernehmen. Alle enthaltenen Meinungen und Informationen dienen ausschließlich der Information und begründen kein Haftungsobligo. Regressinanspruchnahme, sowohl direkt, wie auch indirekt und Gewährleistung wird daher ausgeschlossen. Alle enthaltenen Meinungen und Informationen sollen nicht als Aufforderung verstanden werden, ein Geschäft oder eine Transaktion einzugehen. Auch stellen die vorgestellten Strategien keinesfalls einen Aufruf zur Nachbildung, auch nicht stillschweigend, dar. Vor jedem Geschäft bzw. vor jeder Transaktion sollte geprüft werden, ob sie im Hinblick auf die persönlichen und wirtschaftlichen Verhältnisse geeignet ist. Wir weisen ausdrücklich noch einmal darauf hin, dass der Handel mit Aktien, ETFs, Fonds, Optionen, Futures etc. mit grundsätzlichen Risiken verbunden ist und der Totalverlust des eingesetzten Kapitals nicht ausgeschlossen werden kann.Aussagen über zu erwartende Entwicklungen an Finanzmärkten, insbesondere Wertpapiermärkten und Warenterminbörsen, stellen NIEMALS EINE AUFFORDERUNG ZUM KAUF ODER VERKAUF VON FINANZINSTRUMENTEN dar, sondern dienen lediglich der allgemeinen Information. Dies ist selbst dann der Fall, wenn Beiträge bei wörtlicher Auslegung als Aufforderung zur Durchführung von Transaktionen im o.g. Sinne verstanden werden könnten. Jegliche Regressinanspruchnahme wird insoweit ausgeschlossen. *Affiliate-Link #Danaher #Aktie #Börse

In this episode of Technovation, host Peter High speaks with Ryan Snyder, Senior VP & CIO of Thermo Fisher Scientific, a $40 billion global leader in life sciences. Ryan shares how AI, automation, and data strategy are driving digital transformation—optimizing operations, accelerating clinical trials, and enhancing customer experiences.

As the organ transplant list continues to grow, experts in the transplant diagnostics industry are looking for ways to address the supply and demand challenges within the field. New tactics, like retransplantation and xenotransplantation, and new testing methods, such as HLA testing and transplant diagnostics, are being explored to boost transplant success rates and ensure more patients get the lifesaving transplants they need. As President of Thermo Fisher Scientific's transplant diagnostics division, Tina Liedtky is at the cutting edge of meeting this challenge. She's also passionate about addressing health equity issues, such as ingrained biases regarding gender and race, to help bridge the transplantation gap.Tina joined Meg for a fascinating discussion about the future of transplantation, closing 'the gap', and Thermo Fisher's recent award. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Nicholas Capman of The FDA Group welcomes David Festa, Director of Corporate Quality at Thermo Fisher Scientific, to explore whether pharmaceutical and medical device companies are auditing suppliers too frequently and with the right personnel.With over 25 years of experience in quality management and oversight of tens of thousands of suppliers, David advocates for a more strategic approach that balances quality, compliance, and business needs through "exception-based" auditing.Rather than rigidly adhering to calendar-based audit schedules, David suggests companies should assess suppliers based on performance metrics, risk factors, and the criticality of materials they provide. He challenges the industry norm that every supplier must be visited at predetermined intervals, arguing that well-performing suppliers with stable processes may not require frequent on-site visits.David emphasizes the importance of matching auditor expertise with supplier categories. For example, an auditor with deep knowledge of plastics manufacturing will provide far more valuable insights when evaluating a plastics supplier than someone familiar only with general standards. This targeted approach has helped Thermo Fisher predict quality issues and decrease the percentage of poor-performing suppliers.The conversation explores how post-pandemic practices have evolved, with companies developing more harmonized approaches to global auditing and implementing centralized audit portals. David also introduces the concept of a "supplier pricing index" that quantifies the true cost of poor quality, providing a more accurate picture of supplier value than piece price alone.While ISO certifications provide a foundation for quality systems, David cautions against over-reliance on certifications or imposing unnecessary standards on suppliers. The most effective approach focuses on whether suppliers can maintain control of their manufacturing processes and consistently deliver quality products, regardless of certification status.For companies looking to optimize their supplier quality programs, the key is putting the right people in the right places, implementing quantifiable metrics, and taking a holistic view that integrates quality with other business functions.____The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus in Quality Assurance, Regulatory Affairs, and Clinical Operations. For project or resource needs, visit: ⁠⁠⁠⁠⁠⁠thefdagroup.com⁠⁠⁠⁠⁠⁠.

Francisco Blanco, founder of Conducta consulting, believes the human element in CDMO-sponsor relationships has been lost in the race for efficiency. “I feel like the human component of these relationships has been lost. When I see five-star client services from CDMOs, it's typically not because of the strength of their processes – it's the individual.”Francisco Blanco brings over 15 years of experience from leadership roles at Thermo Fisher and IQVIA to his consultancy Conducta, where he helps life sciences companies navigate complex supply chain transformations, with particular expertise in cell and gene therapy operations.In this PharmaSource podcast episode, Francisco shares crucial insights on how biopharma companies and CDMOs can redesign their customer experience approach, particularly as the cell and gene therapy sector evolves.Read the full interview

How to Build Lasting Customer Relationships and Boost Growth Christoph Senn and Mehak Gandhi propose that B2B companies rethink their growth logic in their recent book Triple Fit Strategy. They lay out the Triple Fit Strategy framework to help companies escape the product-centric mindset and put customers at the heart of their business strategy. Companies using this framework can contribute 10x more to their customers' success and potentially double account values in less than three years. Summary of Triple Fit Strategy Senn and Gandhi suggest a bold new way of doing business that shifts the focus from traditional product selling to a fully customer-centric approach. Their Triple Fit Strategy challenges the old "us and them" mentality, encouraging suppliers and customers to collaborate as if they were a single entity. The result? Businesses that grow far beyond what either party could achieve alone. One Company? At its core, the Triple Fit Strategy puts customers at the centre of three critical areas: planning, execution, and resources. The strategy revolves around a simple and powerful question: What if we - supplier and customer - were one company? Drawing on over two decades of research, the authors argue that companies adopting this framework can contribute ten times more to their customers' success while doubling account values in under three years. Proven Results This isn't just theory. The book shares lessons from global giants like BASF, GE, Microsoft, and Danish shipping leader Maersk, which used the strategy to unlock hundreds of millions of dollars in new opportunities with a New Zealand partner. Backed by a database of over 10,000 cases, the Triple Fit Strategy offers practical tools to bring customers into your company's internal processes, helping to redefine customer relationships, allocate resources wisely, and achieve faster, more meaningful breakthroughs. Business cases The book includes real-life business cases from 3M, Agrana, BASF, Best Buy, BMW, Danone, db Audio, DSM, Evonik, Hillebrand Gori, Indicia, Konica Minolta, Maersk, Marriott, MUREX, Natura, P&G, Sonos, Thermo Fisher, Unilever, Vodafone, and WMF/Schaerer. For Companies Without Large Budgets? Senn and Gandhi outline three practical steps for businesses without a large budget for external consultancy: 1. Create a total business view by analysing business relationships within the Triple Fit canvas. 2. Understand internal politics and identify which stakeholders on both sides will support your case. 3. Foster a mindset of strategic alignment between supplier and customer. For businesses ready to step away from the "product-first" mindset, this book is a game-changer. See more about the book here. About the Authors Christoph Senn Christoph is Adjunct Professor of Marketing at INSEAD and founder/CEO of Valuecreator, a global provider of B2B growth tools and programs. He has taught at leading institutions such as Columbia Business School and the University of St. Gallen. His work has been published in journals, including California Management Review and Harvard Business Review. Mehak Gandhi Mehak is Head of Research & Training at Valuecreator, designing B2B growth accelerator programs and sales strategies for global companies. Her experience spans industries, having worked with Allianz, Maersk, Schindler, Thermo Fisher, and others. She applies the Triple Fit tools to achieve strategic alignment and growth for her clients. TRIPLE FIT STRATEGY: How to Build Lasting Customer Relationships and Boost Growth by Christoph Senn and Mehak Gandhi. Published by Harvard Business Press, ISBN No: 9781647827144 Billy Linehan Billy Linehan is an experienced consultant and advisor, currently serving as Partnership Director at Target Integration, where he leads the Business Connector programme. This initiative builds a network of professionals to drive digital transformation and IT solutions across diverse sectors. As the founder of Celtar Advisers, Billy has guided nu...

Avec la plantation, cet hiver, de micro-forêts aux écoles Édouard-Herriot et Victor-Hugo, les 11 écoles publiques de Bourgoin-Jallieu sont désormais toutes parées de vert ! Réalisés selon la méthode révolutionnaire Miyawaki, sous l'oeil avisé du service Espaces verts, ces aménagements ont impact bénéfique sur son environnement proche et la qualité de vie des habitants. Ils peuvent également inspirer de nouvelles initiatives, comme celle de l'école Claude-Chary et de l'entreprise Thermo Fisher. Grâce à la micro-forêt située sur le terrain de l'entreprise berjallienne, un partenariat a été noué pour proposer aux élèves de CM1 et CM2 un atelier scientifiqueHébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company committed to advancing precision medicine, for a conversation on this space and a new frontier of biomarkers. Quagliata discusses Thermo Fisher's ongoing collaboration with EVERSANA, pharmaphorum's parent company, and that collaboration's investigation of the impact of utilising electronic health record (EHR) data in haematological cancers to support the company's value proposition for ultra-fast next generation sequencing (NGS) with oncomine myeloid solutions. That included a presentation at Frontiers Health 2024, in Berlin, in the deep dive, ‘Overcoming data linkage barriers with tokenization technology: RWE on the use of targeted therapy and its impact on survival in blood malignancies' – presented alongside Dr Pierantonio Russo, Corporate Chief Medical Officer at EVERSANA.

Recorded at NC Life Sciences Organization's Annual Meeting, Heather and Matthew are joined by John Van Hoy, Executive Director of Data Science & Advanced Analytics at PPD, a subsidiary of Thermo Fisher. John is an innovator in advanced analytics for the healthcare and life sciences industries and discusses how PPD is leveraging AI to enhance clinical research. Tune in for an insightful conversation about the benefits and challenges of using AI in drug development!

Welcome to the Rose Woman Podcast, where we explore the cutting edge of health, wellness, and personal empowerment. Today, we have a very special guest - Dr. Michael Snyder, a leader in the field of functional genomics and proteomics, and one of the major participants of the ENCODE project.He has also combined different state-of-the-art "omics" technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of person and used this to assess disease risk and monitor disease states for personalized medicine. Dr. Snyder is the cofounder of Personalis, SensOmics, Qbio @qbioinc, January AI, Filtricine, Mirvie, Protos, Protometrix (now part of Thermo-Fisher). Affomix (now part of Illumina).This is an episode that just might change the way you think about your health and the future of healthcare - don't miss it.In this episode, we cover:Importance of measuring health frequently while people are still healthy to detect early signs of diseaseThe use of wearables, such as smartwatches and Oura rings, plays a crucial role in early detectionBreakdown of omics concepts like genomics, proteomics, and metabolomicsThe role of hormones in aging and the impact of andropause and menopauseEmphasis on the importance of exercise and strength training for overall healthAdvancements in DNA sequencing, mass spectrometry, and wearablesThe importance of continuous data collection and the role of AI in integrating and analyzing large datasetsThe challenges of implementing proactive health monitoring in the current healthcare systemImportance of financial incentives and the role of employers in promoting health and wellnessVision for the future of healthcare with continuous health monitoring and AI-powered personalized recommendationsThe role of hormones and agingHelpful links:Michael Snyder, Ph.D. - Stanford W. Ascherman Professor of Genetics and SnyderlabGenomics and Personalized Medicine: What Everyone Needs to KnowFounder Letter: The New Science on Aging Well by Christine MasonFind Rosebud Woman on Instagram as @rosebudwoman, Christine on Instagram as @christinemariemasonFind Radiant Farms on Instagram @weareradiantfarms Hosted on Acast. See acast.com/privacy for more information.

In this podcast, we spoke with Isha Dey, Senior Scientist, Cell Biology R&D, at Thermo Fisher Scientific about the challenges researchers face in selecting appropriate cell culture conditions due to variability in cell lines, lack of standardized protocols, and inconsistent reagent quality. Thermo Fisher Scientific's new Cell Culture Select Tool was developed to address these challenges by providing specific recommendations for media, FBS, and cultureware for over 150 cell lines, backed by extensive R&D data. Understanding the Challenges in Cell Culture Selection Thermo Fisher Scientific's new Cell Culture Select Tool addresses a persistent challenge in laboratory science: identifying the appropriate cell culture conditions and selecting the right media, supplements, and reagents for different cell lines. The process is complicated by factors like cell line variability, lack of standardized protocols, and inconsistent reagent quality. These issues can introduce variability and impact experimental results, posing a challenge for scientists across labs. “Different cell lines have unique requirements,” explained Isha. “It's challenging to pinpoint optimal culture conditions due to variability in cell line responses. Additionally, there isn't always a standardized protocol across labs or comprehensive information on specific culturing needs. This can make it difficult to select the most appropriate media, supplements, and other materials.” Ensuring a consistent supply of high-quality products is essential for reproducibility in experiments. Thermo Fisher Scientific's trusted brands, such as Gibco, Nunc, and Invitrogen, are known for their quality, which is critical for minimizing variability in experimental readouts. The Inspiration Behind the Cell Culture Select Tool The idea for the Cell Culture Select Tool originated from an update to Thermo Fisher Scientific's online technical reference library. Previously, the website listed recommended media types segmented by cell line culture methods—adherent, semi-adherent, or suspension. While helpful, this list was lengthy and lacked interactive functionality. Isha said, “We realized that we could streamline this information into a user-friendly tool”. “In our R&D labs, we culture over 150 cell lines using various media, supplements, and equipment. By making this data accessible to other researchers through an interactive tool, we hoped to eliminate the guesswork and enable reproducible cell culture success.” The tool now provides recommendations for specific media, supplements, and cultureware for culturing, passaging, and freezing over 150 cell lines. With in-house data supporting 75% of these lines, researchers gain access to the resources and insights gathered from Thermo Fisher's extensive R&D experience. Selecting Cell Lines for the Tool The team started with cell lines listed in their technical reference webpage and expanded the list based on the lines frequently cultured in their R&D labs. These labs conduct heavy cell culture work for various applications, including media development, fluorescence imaging, Western blotting, flow cytometry, transfection, transduction studies, and more. “We wanted to make our R&D data available to researchers for convenience,” shared Isha. “This effort involved many scientists across R&D sites who contributed data and images showing how each cell line appears in recommended media.” Quality and Verification in Thermo Fisher's Labs The tool's data is backed by rigorous testing in Thermo Fisher's R&D labs. Cells are grown in their respective media, culture plastics, and consumables over multiple passages to ensure accuracy. For cancer cell lines, STR profiling and mycoplasma testing are conducted regularly, while stem cell cultures are assessed for pluripotency and purity using imaging and flow cytometry. “Representative images of cell lines, captured using our EVOS imaging system,

The South African Medical Research Council (SAMRC) and Thermo Fisher Scientific are teaming up to create a special center for teaching and training in science in South Africa. This center, set to open in Pretoria in September 2024, will help people learn about critical skills for working in science labs. The center will teach students how to do lab work, use the latest tools, and learn about managing labs and project management skills. Thermo Fisher will provide the tools and supplies, while SAMRC will help students join the program and support them with resources and accomodation. SAMRC, which works to improve health in South Africa, will work with Thermo Fisher to make sure the center provides high-quality learning and breed a new highly skilled cohort of scientists, Clarence Ford speaks to Dr Pritika Ramharack, Senior Scientist from the SAMRC.See omnystudio.com/listener for privacy information.

In this episode of Life Sciences 360, we dive into the evolution of pharmaceutical and biotech manufacturing with our guest, Scott, a seasoned expert with nearly 30 years of experience working with industry giants like Novartis, Biogen, Thermo Fisher, and Merck. Scott shares insights on cell culture technology, mRNA vaccines, and the challenges and innovations in scaling biotech facilities. Discover the impact of collaboration and how organizations like the International Society for Pharmaceutical Engineering (ISPE) are transforming the landscape.Chapters :00:00 - Introduction to Vaccine Technologies00:14 - Importance of Collaboration in Pharma Manufacturing00:22 - The Role of Technology Ecosystems00:30 - Scott's Experience with ISPE00:46 - Motivation Behind Pharma & Biotech Careers01:09 - Welcoming Scott to Life Sciences 36001:19 - Scott's Background & Industry Experience01:45 - Integrating Technology in Pharmaceutical Facilities01:59 - Scott's Current Role & Unique Challenges02:18 - Interview Kickoff: Scott's Career Insights03:11 - The Evolution of Drug Manufacturing03:39 - Insights for Non-Pharma Audiences03:59 - Changes in Vaccine Manufacturing Over the Years04:40 - mRNA Technology and Its Impact05:05 - Encouraging Viewers to Subscribe05:59 - Driving Innovation in Manufacturing Facilities07:01 - Challenges in Scaling New Therapies08:17 - Overcoming Challenges in New Tech Implementation09:03 - The Role of Technology Vendors10:08 - Advancements in Manufacturing Technology11:02 - Evolution of Biotech Processes12:09 - Consulting in Cell and Gene Therapy13:02 - The Infancy of Cell and Gene Therapy13:23 - Introduction to SoulVentum14:01 - Separation from 3M and Vision for SoulVentum15:01 - Scott's Role at SoulVentum15:33 - Scott's Contributions to ISPE17:18 - Identifying Award-Winning Facilities18:39 - ISPE Facility of the Year Criteria20:18 - Global Reach of ISPE Submissions21:41 - Geographical Insights Post-Pandemic22:47 - The Role of ISPE in Pharma Collaboration23:31 - ISPE Communities of Practice24:47 - Forums & Conferences by ISPE26:19 - Local ISPE Chapters & Regional Support26:58 - Scott's Take on Industry Networking28:05 - The Importance of Professional Networks29:05 - Advice on Building a Career in Pharma30:21 - Scott's Mission in the Industry31:42 - Personal Impact of the Work in Pharma32:26 - Patient Stories and Their Motivational Impact33:22 - Closing Thoughts & How to Connect with Scott

Growing up in Eugene, Oregon, Lulu Tsui experienced a unique perspective on cannabis, where it was as common as backyard barbecues. This early exposure shaped her understanding of how cannabis perceptions could differ vastly from mainstream narratives. Lulu's journey led her to co-found On the Revel in 2016, a series of events challenging the status quo of New York City's cannabis industry. Her mission? To foster authentic connections and create a community where diversity and genuine conversation flourish beyond the typical trade show atmosphere. In this episode, host Carly Puch and Lulu dive into a fascinating conversation, exploring personal anecdotes and professional insights that reveal how early exposure and family acceptance can influence one's path in the cannabis sector. Lulu shares invaluable lessons learned along the way, including how humor and strategic media campaigns like "I'm High Right Now" are crucial in reducing stigma and shifting public attitudes toward cannabis. Carly and Lulu explore the importance of building diverse teams and prioritizing self-care in the dynamic field of cannabis. As we move through themes of personal growth, authenticity, and the importance of self-governance, Lulu reflects on how these principles guide her actions and decisions in both business and life. This episode offers juicy insights for anyone interested in the transformative potential of the cannabis industry or who just wants to level up in life, Lulu will inspire. Guest Bio: Lulu Tsui is the co-founder and chief experience officer at On The Revel, the parent company for a collection of curated educational and networking experiences that democratize information for those interested in the regulated cannabis industry. On The Revel events, known as Revelry, are conferences aimed at fostering an inclusive, collaborative, and flourishing cannabis sector. These regular in-person events along with On The Revel's Dope People online membership community, podcast, and virtual experiences, celebrate the diverse people that have been and are currently building the cannabis industry in the aim of developing its gold standard, with opportunities for all. Lulu is seasoned in Experience Design (XD) and User Experience (UX) with 15+ years of experience leading research, strategy, and design for enterprise software, Software as a Service (SaaS), mobile, and touchscreen technologies. Lulu applies her vast XD and UX expertise across verticals in the cannabis industry while championing ways to normalize and destigmatize cannabis and entheogens. Lulu has designed entire enterprise systems and introduced cross-platform mission-critical apps for clients Bloomberg LP, Mastercard, The Leukemia & Lymphoma Society, John Hopkins University, Roche, Thermo Fisher, Pearson, and McGraw-Hill. Lulu designed a software platform with Root Sciences aimed at supporting and standardizing operations and data for cannabis/hemp extraction, distillation, and post-processing. She also served as the principal experience designer for Chill, a cannabis e-commerce order and delivery platform. Along with On The Revel, Lulu serves as President of the Cannabis Media Council, an organization dedicated to destigmatizing and normalizing cannabis using the power of traditional media, and User Experience and Research Advisor at Oakland Hyphae, founders of the Oakland Psychedelic Conference and the Psilocybin Cup. https://ontherevel.com https://www.revelryny.com  Thanks for listening to another episode. Follow, review, and share to help Consciously Clueless grow! Connect with me: https://www.consciouslycarly.com/ Join the Consciously Clueless community on Patreon: https://www.patreon.com/consciouslycarly Connect on Instagram: https://www.instagram.com/consciously.carly/ Connect on Facebook: https://www.facebook.com/consciously.carly.blog Music by Matthew Baxley

“The industry is back, and we're uniquely positioned to provide end-to-end services, including clinical trials. That's what we mean by CDMO plus CRO – it's a complete 360-degree set of operations,” says Dr. Anil Kane, Executive Director and Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific. Dr. Kane leads Thermo Fisher's technical and scientific initiatives, bringing extensive experience in pharmaceutical development and manufacturing. His expertise spans multiple modalities, from small molecules to advanced therapies, positioning him at the forefront of innovative drug development solutions. Speaking to the PharmaSource podcast at CPHI Milan, Dr. Kane explained Thermo Fisher's latest initiative, Accelerator™ Drug Development, which combines their Contract Development and Manufacturing Organisation (CDMO) capabilities with Contract Research Organisation (CRO) services from their PPD acquisition. This integrated approach aims to streamline the complex journey from pre-clinical development to commercialisation, offering a truly connected and customisable suite of services. The 2021 acquisition of PPD marked a pivotal moment in Thermo Fisher's evolution, enabling the creation of a comprehensive service offering that spans the entire drug development spectrum. This integration brings together: Drug substance development Drug product development Clinical trial packaging and labeling services Full clinical trial management Specialised GMP laboratory testing Regulatory documentation support “This combination of services brings efficiency, reducing cost and time for our partners to run drug development from very early stage, through clinical phases, to approval and bringing medicines to patients faster,” explains Kane. “We help our clients even put documentations together for IND, NDA, and other regulatory submissions.” Read the full interview on PharmaSource

Check out the New Bond account with an initial APY of 6.9%, only at https://public.com/csi We are discussing Twist Bioscience (TWST), a fascinating biotech company that helped revolutionize DNA synthesis -- but on silicon wafers. Of course Chip Stock Investor is interested! Nick and Kasey explore Twist's technology, market potential, and the competition they face from big players like Merck and Thermo Fisher. Plus, a closer look at the financials and future prospects of Twist Bioscience. However, stick around for a bonus analysis at the end on Analog Devices (ADI), how it might be powering Twist's DNA-on-silicon platform, and ADI might be the better investment choice long term. Don't miss out on this in-depth CSI episode! Join us on Discord with Semiconductor Insider: https://ko-fi.com/chipstockinvestor Supercharge your analysis with AI! Get 15% of your membership with our special link here: https://finchat.io/csi/

Compliance with environmental sustainability goals is no longer optional for medtech companies serving global healthcare markets. Thermo Fisher has made it a mission to be a leader in thought and actions in meeting Scope 1, 2 and 3 needs. Corporate VP and head of sustainability Meron Mathias explains the company's sustainability aims and methods, for itself and its customers, and stresses the importance of continuing to enhance patient care with innovative products at the same time.

Welcome to episode 054 of Life Sciences 360.In this episode of Life Science 360 ,Today, we are thrilled to have Lisa Sellers, the CEO of Vector Labs, as our special guest. Lisa shares her incredible journey from working at big names like Thermo Fisher and 10x Genomics to leading Vector Labs, a trusted manufacturer of reagents and critical components in the life sciences sector.In this episode, we dive deep into:- Lisa's transition from being an industry professional to becoming a CEO- The unique challenges and benefits of working in smaller companies- Vector Labs' strategic acquisitions and mergers to expand their product portfolio- The impact of Vector Labs in the pharmaceutical, diagnostic, and academic sectors- Lisa's passion for mentorship and her efforts to inspire the next generation in STEM fieldsChapters :00:00 - Introduction00:41 - Welcome Lisa Sellers01:12 - Lisa's Career Journey02:37 - Transition to CEO05:00 - Comparing Big Companies to Smaller Companies09:28 - Vector Labs' Product and Service Overview14:25 - Recent Acquisitions and Expansions17:20 - Role of Private Equity in Vector Labs20:28 - Challenges in Protein and Glycan Detection23:54 - Vector Labs' Diverse Customer Base26:59 - Managing Priorities and Resources29:00 - Vision for Vector Labs in the Next 5 Years32:39 - Lisa's Mentorship and Community Involvement37:17 - Key Leadership Qualities in STEM41:28 - Final Thoughts and ClosingStay tuned and don't forget to subscribe for more in-depth conversations with leading scientists and innovators in the life sciences field!----- Links:*Lisa Sellers: (https://www.linkedin.com/in/lisa-sellers/)*Vector Labs: (https://www.linkedin.com/company/vector-laboratories/)*Harsh Thakkar LinkedIn ( https://www.linkedin.com/in/harshvthakkar/ )*Listen to this episode on the go! 

Listen to the conversation as they discuss:How health equity is a key component of Thermo Fisher's core business.How Thermo Fisher leverages its capabilities and customer relationships to further its impact.Initiatives that improve health equity through accessibility to drug-resistant HIV testing, next-generation sequencing to diagnose lung and breast cancer in 30 underserved countries, increasing the accessibility to and diversity in clinical trials, and more.New programs in 2024.

Dr. Blackburne shares insights into:The challenges of recruiting women and minority groups for clinical trials, noting the logistical and societal barriers they face.Innovative solutions, such as telemedicine and flexible scheduling, to make trial participation more accessible. Recent advances in clinical research, including a groundbreaking preeclampsia test and contributions to COVID-19 vaccine trials, highlighting Thermo Fisher's pivotal role in these developments.

In der heutigen Folge von "Alles auf Aktien" sprechen die Finanzjournalisten Laurin Meyer und Nando Sommerfeldt über Bestechungs-Ärger bei Adidas, zehn Blockbuster-Hoffnungen von Bayer und Warren Buffetts neueste Verkäufe. Außerdem geht es um Apple, Microsoft, Nvidia, Broadcom, Micron Technology, Palantir, Berkshire Hathaway, BYD, Carl Zeiss Meditec, Evotec, Porsche AG, Qiagen, Thermo Fisher und Deutsche Bank. Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

When you have a good thing going you often want it to last forever, but we know that can never happen. Life and the world around us are fluid, dynamic, and we're always finding the balance of fighting or harnessing entropy and inevitable change.As we encounter unexpected changes, we see them as chances to evaluate the foundations of our podcast's success while finding opportunities to evolve it and make it even better. Join us for a reflection of where we are, how we got here, and a sneak preview at what's to come. We're here to assure you, evolution is a good thing!

Steve Becker is committed to improving human health by unlocking the power of molecular diagnostics. In the world of medical devices and diagnostics, you might think the latter falls under the purview of the former, says Steve, yet: “from a regulatory standpoint, diagnostics is covered by a lot of the medical device rules.” Unlike medical devices like implants, however, “diagnostics is really the ability to measure your body, whether you're healthy or sick; and if you are sick, what's making you sick. Helping to uncover your health status and what you can do to improve is really the heart of diagnostics.”  In this episode, Steve shares the lasting lessons learned during his stints at Thermo Fisher, Quest Diagnostics, Agilent, and GE Healthcare, where he directed sales, global marketing, business development, and licensing. Learn how to navigate within a constantly changing healthcare business landscape, from the first steps toward launch to the regulatory requirements and cultural differences that can affect development, distribution, and product adoption.   Going to market on one's own is a big task, says Steve – find the right partners to mitigate the commercial regulatory tasks and technical risks. Ultimately, the company whose name is on the product assumes the liability – “they're the ones on the hook” – but relying on specialists along the way improves your chances of a streamlined launch.  During his tenure at Quest Diagnostics, the company built a “global diagnostics network,” pooling the capabilities, diagnostics insights, samples, testing and sharing of leading companies into one place. In the end, Quest brought the first Zika test to market, reliant upon colleagues.  In fact, choosing your initial target audiences can come into play even during development, as “diseases become more localized and companies are made for those markets,” Steve adds. Pay attention to “how to get paid for what you do,” your reimbursement strategy. In diagnostics, for example, ask yourself:  Is it going to measure what we say it's going to measure? (Analytic or clinical validity)  Can we do anything with the information? (Utility)  Interestingly, reimbursement can often become political; for example, in the US it's widely accepted that breast cancer can come with a genetic indicator (the BRCA gene) – and the patient can take prophylactic steps or opt for watchful waiting. In contrast, Steve says that:  In a single-payer system, if you were 49 you could take the [BRCA] test; if 50, no test. The calculation includes risk, quality of life, total cost – someone makes a decision, snapped the line, and that's where it landed.  Add to that differences stemming from culture and tradition, and it makes sense to work with local, in-country partners to navigate your go-to-market strategy, especially with regard to regulatory requirements.  To date, Steve says that European companies would often launch first domestically and then in the US because it was easier, but that's starting to change as the EU changes its regulatory stance.  Regulations are stricter now in Europe, with liability going as far back as the manufacturer – for translation quality, for example. Diagnostic tests are now treated more like a medical device, including review by regulatory bodies, etc. – it's a lot more work but it's a good thing.  Think globally but act locally, Steve adds. You may use the same assay (investigative procedure for qualitatively or quantitatively measuring the presence, amount, or functional activity of an element) as in the US but a local company can handle the technology, packaging, regulatory requirements, approvals, and clinical evidence and market under THEIR brand, with their own branding and local language. This happens consistently, across IV diagnostic companies – Abbott, Siemens, Roche, Thermo Fisher – and all of them have to treat each of their launches “locally,” working with in-country regulatory bodies to get approvals.  And vice versa: one of the first Covid tests distributed in the US was manufactured by a Korean company but marketed as a known American brand. In fact, working with companies around the world has interesting and complex effects on branding – “you'll get a multi-national brand but lose some efficiencies,” according to Steve.  In the end, Steve's advice is ever so simple: “You don't want to take risks in the healthcare world.”    Links:  LinkedIn: https://www.linkedin.com/in/stevebecker/    Connect with Wendy - https://www.linkedin.com/in/wendypease/  Music: Fiddle-De-Dee by Shane Ivers - https://www.silvermansound.com 

The fields of Cell and gene therapy are booming and poised to change the treatment and prevention of disease. These research areas require the transfer of genetic material to cells, and viral vectors are commonly used here. Specifically, adeno-associated virus (AAV) and lentiviral vectors (LVV) are vectors of choice. We're joined for this episode by MinGin Kim and Kimberly Gomez, both scientists at Thermo Fisher. With backgrounds and expertise in the areas of cell and gene therapy, they help explain what all the excitement is about and how AAV and LVV are used. We hear about some of the challenges associated with viral vector work and get to hear about how digital PCR (dPCR) and good assay design are helping overcome many of these challenges to enable research and the biopharmaceutical industry. As you might expect from Absolute Gene-ius, you also get to hear their respective career path journeys and some really interesting lab stories.Visit the Absolute Gene-ius page to learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

Would you ever consider leaving a secure and high-ranking position as a CEO at IBM Europe to join a startup as merely the 16th employee? Josh Geballe took that exact leap, moving away from the corporate security he knew to embrace the thrills and challenges of a startup, guided by what he describes as his "gut feeling."Josh's openness and straightforward approach are genuinely refreshing, yet it's clear that navigating such significant career shifts involves much more than instinct alone. It requires courage, foresight, and a willingness to face the unknown head-on.Since 2022, Josh has been a pivotal figure at Yale University, leading as the Managing Director of Yale Ventures (official website). In this role, he has been instrumental in spearheading the university's innovation ecosystem, catalyzing growth and collaboration across various disciplines.Reflecting on our days at Yale School of Management, I can't help but feel that having someone like Josh around back then would have been incredibly beneficial. His innovative spirit might have even lured me away from a traditional path in finance to explore the dynamic world of startups.In this podcast episode, Josh generously shares the wisdom gained from his two decades of varied experiences, which have been filled with both formidable challenges and substantial impacts. Here are some highlights from our conversation:As the COO during Connecticut's COVID-19 health response, Josh faced a public health crisis of unprecedented scale, the likes of which no MBA curriculum could ever anticipate or equip its students to handle. (press conf link)After spending over a decade at IBM in London, Josh made a decisive career shift to a startup in Connecticut that was later acquired by Thermo Fisher. This move exposed him to the intense realities of startup culture, where rapid growth can often be as daunting as it is exhilarating.At Yale, his current role involves driving the campus-wide innovation efforts. He elaborates on how he fosters a culture of innovation that supports the daily pursuits of students, faculty, and the broader university community, helping to translate abstract ideas into tangible, impactful realities.Tune in to this episode to gain insights from Josh's extensive experience with career transformations and his strategic approach to overcoming the obstacles that accompany change. It's sure to inspire and educate anyone interested in the intersections of innovation, leadership, and personal growth.Josh Geballe: https://www.linkedin.com/in/joshgeballe/ Vince Chan: https://www.linkedin.com/in/thevincechan/Chief Change Officer: Make Your Laws of Change.#1 Careers US on Apple Podcasts. Subscribe and be inspired!

Agende uma reunião gratuita com os consultores da Nord Wealth

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Orchard has set a record-setting price tag of $4.25 million for its gene therapy Lenmeldy, with hopes of convincing insurers to cover it. The FDA panel has backed broader use of J&J and Bristol Myers cell therapies for myeloma, despite concerns about early death risks. Capstan raised $175 million to advance an autoimmune disease treatment. Following a buyout, Orchard received FDA approval for its rare disease gene therapy. Bluebird, facing financial struggles, took on $175 million in debt financing to extend its runway. Bristol Myers' cell therapy Brexanzi received approval for certain adults with hard-to-treat forms of leukemia or lymphoma. The gene therapy landscape continues to evolve, with advancements in treatments and approvals. Biopharma Dive provides in-depth coverage of the latest news and trends in the biotech and pharma industries.Transitioning to the next news, Thermo Fisher and Bayer have partnered to develop companion diagnostics to identify potential patients for Bayer's precision cancer therapies. Insulet has named Ana Maria Chadwick as CFO, while Johnson Matthey plans to sell its medical device components unit for $700 million. Medtech layoffs continue in 2024, with companies like Medtronic and Baxter announcing employee cuts. Intuitive aims to stay ahead of competitors with a new surgical robot, and the FDA has issued warning letters related to plastic syringes made in China. The medtech industry is seeing a growing focus on digital health and AI, with companies embracing new technologies and treatments. Overall, the industry is evolving rapidly with advancements in technology and treatments reshaping the landscape.

Part 2 of 3. My guest for this week's episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science. Before Thielsen, Mike was the CEO of Phitonex, which Thermo Fisher acquired. He was also VP & GM of Informatics at BD Life Sciences and was the CEO of FlowJo before its acquisition by BD. He has also taught at MIT Sloan, authored 10 patents, and won the 2019 International Society for the Advancement of Cytometry Innovation Award.

Scott Wapner and the Investment Committee debate the state of stocks as the S&P tries to extend its record high. Plus, Bill Baruch is making some move in his portfolio, he calls in with the details. And later, we've got some calls of the day on Regeneron, Thermo Fisher, Darden Restaurants and more. Investment Committee Disclosures

Part 1 of 3. My guest for this week's episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science. Before Thielsen, Mike was the CEO of Phitonex, which Thermo Fisher acquired. He was also VP & GM of Informatics at BD Life Sciences and was the CEO of FlowJo before its acquisition by BD. He has also taught at MIT Sloan, authored 10 patents, and won the 2019 International Society for the Advancement of Cytometry Innovation Award.

Global life sciences company Thermo Fisher Scientific has announced the launch of its 2024 Engineering Apprenticeship Programme, coinciding with World Engineering Day. Delivered in partnership with further education and training agency SOLAS, applications are open until 24 March. Information on the programme is available here. The contract pharmaceutical development and manufacturing campus at Currabinny, Carrigaline, Cork, is accepting applications for an Electrical and Instrumentation Apprenticeship and a Mechanical Apprenticeship as part of its four-year salaried apprentice programme. Lead Craftsperson and Apprentice Programme Coordinator at Thermo Fisher Scientific's Cork site, Declan Carroll, said: "Thermo Fisher Scientific's apprenticeship programme is the perfect opportunity for anyone who wants to kick-start a practical career in electrical and instrumentation, or mechanical engineering, in a dynamic industry. The apprentices are a valued part of our team and many of them choose to continue working with us, once the programme is finished and they are fully accredited craftspeople. "Each year, we look for candidates who are enthusiastic, eager to learn and want to work in a team environment. The programme would suit anyone interested in STEM subjects in school. Someone who is curious, likes to solve problems, and has a flair for engineering, science and machinery." For the duration of the programme, an apprentice's time is divided between the Cork site, training centres and third-level universities, where they complete on-the-job training and the SOLAS curriculum modules. Each apprentice is paid a salary for the duration of the apprenticeship programme. On successful completion of the internationally recognised apprenticeship (Level 6 Advanced Certificate), each apprentice is eligible for consideration for entry into a related Level 7 and 8 Degree programmes provided by the universities. Sarah Aherne, who is currently in her first year of the Electrical and Instrumentation apprenticeship programme at Thermo Fisher, said: "I chose an apprenticeship after school as I am a hands-on learner. The apprenticeship allows me to develop technical skills and put them into practice every day, and then learn the theory during the college time built into the programme." "No two days are the same on site and it's great to know that I'm contributing to the delivery of life-saving medicines." Thermo Fisher Scientific's Cork campus is an active pharmaceutical ingredient development and manufacturing site and is part of its Pharma Services business. The team is expert in taking chemistry from laboratory scale development through to clinical and large-scale commercial manufacturing. Further information on the programme is available at https://jobs.thermofisher.com/global/en/ireland-apprentice-programme. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, LinkedIn, Facebook, Instagram, TikTok and Snapchat.

Thermo Fisher's Q4 2023 earnings call, unedited

Welcome back Gene-iuses!  Jordan and Cassie kick us off with a fun teaser of what's to come in Season 2 of the Absolute Gene-ius series.   We'll be featuring another great season of interesting guests, all using dPCR to progress their diverse research applications. This includes conversations about reproductive biology, liquid biopsy and transplantation research, CAR-T research, the role of bioinformatics in PCR assay design, micro-RNA analysis, differential gene expression analysis, and of course Cassie's Career Corner, where we get to learn about people behind the science.   This teaser, like every episode of Absolute Gene-ius, has the fun baked in to keep it all light and interesting too.  You might even hear some digital PCR jokes!  Visit the Absolute Gene-ius page to access the entire first season and to learn more about the hosts and the Applied Biosystems QuantStudio Absolute Q Digital PCR System.  

Today, we're listening to a session Jörgen hosted at the Employer Branding Strategies Conference with Kenty Brumant. Together, they chat about employer brand strategy, activation, and measurement, and why Thermo Fisher has a company page on Stack Overflow. Kenty Brumant is the Senior Manager of Talent Attraction and Employer Brand at Thermo Fisher Scientific. Kenty Brumant on LinkedIn: https://www.linkedin.com/in/kentybrumant/ Careers at Thermo Fisher: https://jobs.thermofisher.com/global/en Subscribe to this podcast: https://employerbrandingpodcast.com Measure your employer brand: https://employerbrandindex.co Thanks for tuning in!

Feedback XXL! Tobias Kramer und Christian W. Röhl mit der zweiten und dritten Meinung zu den Dickschiffen unter den aktuellen Aktien-Favoriten der Community – u.a. mit dem milliardenschweren Musik-Multi hinter Taylor Swift, Billie Eilish, Rammstein und Kerstin Ott. Außerdem dabei: Teure Sportschuhe, morgenstarke Burger, ein E-Commerce-Wachstumswunder mit deutschen Wurzeln und eine kanadische Großbank mit 5% Dividendenrendite.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über die plötzliche Champagnerlaune an den Märkten, die Kurshausse bei ProSiebenSat.1 und die abrupte Dollar-Schwäche beim MSCI World. Außerdem geht es um iShares Global Clean Energy (WKN: A0MW0M), Invesco Solar ETF (WKN: A2QQ9R), iShares Core MSCI World (WKN: A0RPWH), Invesco EQQQ Nasdaq-100 (WKN:A2N6RV), ARK Innovation (WKN: A14Y8H), iShares MSCI Global Semiconductors ETF (WKN: A3CVRA). Delivery Hero, Apple, Alphabet, Home Depot, CRH, Berkshire Hathaway, Linde, Eli Lilly, International Flavor & Fragrance, VWWare, Vertiv Holdings, Suncor Energy, Meta, Exxon Mobil, Uranium Energy, Nu Holdings, Helix Energy Solution, TSMC, Avis, Visa, Oracle, Boeing, Canadian National Railway, Thermo Fisher, Block, Fortinet, Booking Holdings, Splunk, Cisco Systems, Microsoft, Horizon Therapeutics, Abcam, Novo Nordisk. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hier findet ihr alle AAA-Bonus-Episoden bei WELT – dazu den AAA-Newsletter und noch weitere WELTplus-Inhalte: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Philipp Vetter und Holger Zschäpitz über den Kurssprung bei der Deutschen Bank, Metas unfreiwillige Argumente für seine Ankläger und Luxus-Enttäuschung bei Kering. Außerdem geht es um Alphabet, Microsoft, Amazon, Deutsche Telekom, Beiersdorf, Porsche AG, Gucci, Worldline, Danaher, Thermo Fisher, Mobileye, SolarEdge Technologies, Plus500, WalkMe, InMode, Nano Dimension, Cyberpark Software, CAB Payments Holdings, Adyen, Kaspi, Paypal, Block, Mastercard, Visa, Nu Bank, Inter & Co., Affirm, Wise, Coinbase, Amazon, Xtrackers MSCI Fintech Innovation ETF (WKN: DBX0R1), Invesco KBW NASDAQ Fintech (WKN: A2DHWJ), Global X FinTech ETF (WKN: A2QPBZ). Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

APAC stocks traded mixed following a firmer lead from Wall Street as eyes turned to earnings from heavyweights Microsoft and Alphabet.Microsoft shares rose 3.9% and Alphabet tumbled 5.9% with cloud growth in focus. ES and NQ dipped slightly as Microsoft issued its guidance.ASX 200 slipped and AUD/USD was boosted by hotter-than-expected Australian CPI, which led to hawkish revisions to some analysts' RBA calls.Israeli occupation forces stormed a town in the West Bank, Israel said two projectiles were launched from Syria, Hezbollah said it struck an Israeli post with guided missiles.European equity futures are indicative of a slightly firmer open, with the Euro Stoxx 50 +0.1% after cash markets closed +0.6% yesterday.Looking ahead, highlights include German Ifo, US New Home Sales, BoC Policy Announcement, ECB's Lagarde, BoC's Macklem & Rogers, and Supply from the UK, Italy, Germany & US.Earnings: ADP, Heineken, Santander, Ubisoft, Reckitt Benckiser; Meta, Thermo Fisher, T-Mobile, IBM, ADP, Boeing.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

European bourses & US futures are in the red with the breakdown heavily influenced by a busy corporate docketMicrosoft +3.6% & Google -6.8% in the pre-market, ahead of heavyweights include Meta & BoeingDXY eclipses Monday's best to the modest detriment of peers, AUD gives up post-CPI gains & JPY continues to test 150.0Core fixed benchmarks lose initial upward momentum despite strong auctions, modest pressure emanating from above-forecast German IfoA contained and limited session for the commodity space as the pace of geopolitical updates slows somewhatLooking ahead, highlights include US New Home Sales, BoC Policy Announcement, Fed's Powell, ECB's Lagarde, BoC's Macklem & Rogers, and Supply from the US. Earnings: Meta, Thermo Fisher, T-Mobile, IBM, ADP, Boeing.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über Peak Nvidia, langweilige Zahlen bei Thyssenkrupp Nucera und die Favoriten des klugen Geldes. Außerdem geht es um Tesla, Commerzbank, Deutsche Bank, Zalando, Vonovia, TAG Immobilien, Fortescue Metals, VinFast Auto, VW, Mercedes-Benz, BMW, Carvana, Archer Aviation, Apple, Microsoft, Tesla, Berkshire Hathaway, Amazon, Procter & Gamble, Johnson & Johnson und die Google-Mutter Alphabet. Amazon, Meta, Alphabet, Visa, Comcast, Uber Technologies, Wells Fargo, Mastercard, Fiserv, Cigna, American International Group, Intuitive Surgical, ServiceNow, Uber, Workday, Disney, IBM, Intel, Walmart, Exxon, Thermo Fisher, Caterpillar, Ford, McDonalds, Pepsi, Pfizer, Costco, Home Depot, Lyxor MSCI All Country World ETF thesaurierend (WKN: LYX00C), iShares Euro Government Bond 7-10y thesaurierend (WKN: A0X8SM), iShares USD Treasury Bond 20+yr thesaurierend (WKN: A2JKTZ), Euwax Gold II (WKN: EWG2LD), Lyxor Smart Overnight Return (WKN: LYX047), Deka Deutsche Börse Eurogov Germany Money Market (WKN: ETFL22). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

A couple of weeks ago we had our Think Tank episode where we've asked an interesting question to see how our guests might implement or respond to this particular scenario. And today is no exception... I got to ask our amazing guest, Karen Brieger, the Senior Vice President of People for an amazing brand called Therapy Brand “What would happen if native digital SWAT teams were deployed in organizations to solve vexing problems?” In this episode, you'll hear her insights and strategies for leveraging AI tools to enhance the hiring process. With an extensive background as the SVP of People Operations and Chief People Officer at renowned companies like Thermo Fisher, Smiths Medical, and Investors Bank and Trust, Karen's experience speaks volumes. Pay special attention to how her rich experience and fresh outlook on the role of technology in the workplace offer unique perspectives that will surely leave you pondering. ---- Leading with Authenticity Our conversation highlights the significance of authentic leadership in creating a psychologically safe environment. Karen Brieger underscores the importance of being true to oneself, which paves the way for others to do the same. She shares a personal anecdote about cracking jokes during an interview, which prompted relief and a sense of ease among her colleagues. Karen believes that her own authenticity sets a positive example, allowing others to feel comfortable in expressing their true selves. She notes, "And if I'm not going to be authentic, then have I created a psychologically safe space for others to be authentic? So, it's got to start with me at the top, right? It has to start with the CEO too." This perspective emphasizes that authentic leadership not only fosters personal growth and satisfaction but also influences the overall cultural dynamics within an organization. Outsourcing Solutions Through AI Teams One of the most pressing questions is the potential for outsourcing complex tasks to AI-empowered teams, thus maximizing efficiency and cost-effectiveness. As Karen points out, this strategy aligns with current practices of engaging consultants and experts. "If I could use this group that has the power of this AI tool to help solve the problem or do the work for me in half the time, a quarter of the time, in maybe a more creative, productive way, it's going to cost me less, it's going to get me a better outcome. So why wouldn't I?" -- Karen Brieger It becomes evident that the convergence of AI and digital natives presents a transformative opportunity for organizations. By harnessing the creativity of youth and the power of AI, businesses can overcome complex challenges... reshape traditional problem-solving paradigms and position themselves for success in a digitally driven future. Addressing Industry-Specific Knowledge and Problem Solving "How much industry knowledge depends on the problem, right? How much industry knowledge is needed to help guide what the solution is?" - Karen Brieger From a structural standpoint, Karen emphasizes the importance of domain knowledge in tackling complex problems within specific industries. "How much of that just, and that's learned. That's to me those are learned skills. And how essential, with this group, are they there yet? Have they learned those sorts of skills? And is that going to be a challenge in...

Henrietta Lacks' descendants reach a settlement with biotechnology company Thermo Fisher after the use of her cervical cells, harvested by Johns Hopkins without her knowledge, have reaped billions of dollars for the pharmaceutical industry.

Episode 72. Gertrude Nonterah is a Medical Communications professional at Thermo Fisher and the creator of The Bold PhD, where she helps PhDs navigate non-academic careers. Gee did a postdoc at UC San Diego, PhD at Temple University, and undergrad degrees at Virginia Commonwealth University and PennWest Edinboro. Check out her blog and newsletter at: www.theboldphd.com

European bourses are generally subdued with the Euro Stoxx 50 weighed on by LVMH -4.4%Stateside, futures are more contained pre-FOMC and as participants digest after-hours MSFT & GOOGL updatesDXY continues to slip amid ongoing JPY strength with EUR benefitting as the three regions near policy announcements; AUD lags post-CPICrude benchmarks a touch softer intraday after Tuesday's multi-month peaks with base metals in-fitting, XAU benefits from the USDEGBs are cagey with drivers limited while USTs tick higher and more so at the short-end pre-FedLooking ahead, highlights include US New Home Sales, FOMC Policy Announcement and Fed Chair Powell's Press Conference. Earnings from Boeing, Meta, Thermo Fisher, & Coca-Cola.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über ​​Hoffnungen bei Neuemissionen, die Chipotle-Fantasie und drei Szenarien für die Sommer-Börsen. Außerdem geht es um BYD, Danaher, Merck, Thermo Fisher, Disney, Boeing, Airbus, Cava Group, Evotec, Krones, Software AG, Palantir, Duo Lingo, AppLovin, Nu Holdings, Aroundtown, Siltronic, Adtran, Suse, United Internet, Invesco EQQQ (WKN: 801498), Lyxor ETF S&P 500 (WKN: LYX0Q9), iShares Exponential Technologies ETF (WKN: A14U1M), Xtrackers S&P 500 Equal Weight ETF (WKN: A1106A), Vonovia, Brenntag, Adidas, MTU Aero Engines, Bayer, Deutsche Börse, Infineon, Apple, Microsoft, Saudi Aramco. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Thermo Fisher TMO Stock & Salesforce CRM Stock (S&P 500 10 to 30) Want to know more about what I do? https://goo.gl/MQG2k5 Full-time independent stock market analyst and researcher! STOCK MARKET RESEARCH PLATFORM (analysis, stocks to buy, model portfolio) Stock Ideas and Analyses for The Small Investor: https://goo.gl/GdKEoe I am also a book author: Modern Value Investing book: https://amzn.to/2lvfH3t More at the Sven Carlin blog: https://svencarlin.com/ Check out Modern Value Investing YouTube: https://www.youtube.com/c/InvestwithSvenCarlinPhD

Notes from a Barron's chat with the CEOs of BorgWarner, Thermo Fisher, Blackstone, and Nasdaq. Plus fashion tips. Learn more about your ad choices. Visit megaphone.fm/adchoices